Background: Although some genes associated with increased risk of Alzheimer Disease (AD) have
lzheimer Disease (AD [MIM 104300]) is a common, complex genetic disorder with a prevalence rate of 5% to 10% and an incidence that increases exponentially A Clinical manifestations of the disease are associated with alterations in some or all of the following neurotransmitter networks: the forebrain cholinergic system, noradrenergic system, and telencephalon somatostatinergic system. 1 In addition, the interaction of cholesterol metabolism, inflammatory processes, and APOE has been implicated in contributing to the pathogenesis and/or progression of the disease.
Because evidence of genomic variation in association with LOAD is increasingly emerging in both mutational and susceptibility loci, it is becoming increasing clear that complex neurodegenerative processes underlie development and susceptibility to LOAD. More recently a large number of genes have been implicated as a risk to LOAD, but only a few of these associations have been replicated. [2] [3] [4] Besides APOE4, which is currently the most established and validated genetic risk factor for LOAD in most populations, 5 the ACE gene emerged as another potential risk factor for LOAD.
Specifically, the A-262 T polymorphism (rs4291) in the promoter region of the ACE gene showed strong association with LOAD and was present in up to 35% of subjects with AD in five independent populations representing approximately 3,100 individuals. 6 Moreover, recent meta-analysis has determined a highly significant association of a 289 bp ALU insertion/deletionpolymorphism (I/D) in intron 15 in the ACE gene for patients with AD. 6, 7 Another interesting candidate gene is the oxidized low-density lipoprotein (LDL) receptor gene ORL1. 8 One environmental factor whose role in AD pathogenesis remains controversial based on systematic review of case-control and cohort studies is smoking history. [13] [14] [15] Several studies have demonstrated that smoking is inversely proportional to AD progression as a risk factor due to the demonstrated ability of nicotine to stimulate neurotransmitter systems that are compromised in AD. Others have defined potential risk, especially in association with heavy smoking. [15] [16] [17] Another important environmental factor implicated in AD is cholesterol. Increased serum concentrations of total cholesterol, low density lipoprotein (LDL) cholesterol and APOE have been reported in patients with AD. [18] [19] [20] Although cholesterol has been implicated in contributing to disease progression and etiology, and numerous hypotheses have been advanced to explain its role in disease pathogenesis, how APOE or other candidate genes investigated here mechanistically promote etiology, progression, or pathology remains to be defined.
The influence of environmental factors is further emphasized in a recent study of 4,615 subjects where authors reported significant association of increasing age, less education, and presence of APOE4 allele with AD, and decreased risk in association with use of non-steroidal antiinflammatory drugs, daily coffee consumption, wine consumption, and regular physical activity.
The study was unable to demonstrate significant association with respect to family history of dementia, smoking, gender, depression history, estrogen use, hypertension, or cardiovascular conditions. However, while the authors adjusted for gender, education, and age, no adjustment was made for the genotype; thus it is unclear whether risk of other factors was influenced by presence of the APOE4 allele or other candidate genes proposed for AD. 
Material and Methods

PMRP
The current study was conducted using a nested case-control design utilizing DNA and phenotypic data from a subset of participants in the PMRP cohort, details of which have been published previously. 22 The PMRP is a population-based biobank located in central Wisconsin.
Nearly 20,000 residents aged 18 years and older have participated, consenting to medical record access for purposes of defining phenotype and provision of a blood sample from which DNA, plasma, and serum were extracted and banked. The study was approved by the Marshfield Clinic Institutional Review Board, and all subjects or their medical power of attorneys gave written informed consent prior to study participation.
Phenotyping of cases and controls
For the present study, the Marshfield Clinic medical records were searched electronically to identify potential cases of AD and controls. Chart abstraction was used to confirm case status and the required inclusion criterion of age ≥65 at diagnosis. 
Data abstraction
The highest value for total cholesterol, LDL cholesterol, high density lipoprotein (HDL) cholesterol, diastolic and systolic blood pressures, log highest triglycerides, and highest quartile of C-reactive protein were abstracted from the electronic medical records for cases before diagnosis of AD was confirmed and for controls before the date of MMSE administration. The highest values were chosen, assuming that they had occurred before administration of any medication to alter these levels. This may lead to overestimations of the actual values, such as occurs with "white coat hypertension", but would only lead to bias if it differentially occurred in the cases or controls. Lifetime smoking information (never smoker, past smoker, present smoker) was collected from the self-administered study questionnaire that PMRP participants complete at the time of their enrollment in PMRP. Statin use was abstracted from the medical records. No other medication use was recorded.
Genotyping
Primer design: Both the amplification and extension primers were designed using the Assay Designer 2.05-software from Sequenom. This software designs the primers used for amplification and the base extension reactions. It also identifies the appropriate termination mix to use in the homogeneous mass extend (hME) or in the I-PLEX reactions. The amplification primers were designed with a 10-mer-tag sequence ACGTTGGATG to increase their mass so that they would fall outside the range of detection of the matrix assisted laser desorption/ionization time-of-flight (MALDI-ToF) mass spectrometry. The amplification and extension primers and the expected product sizes are presented in table 1. The Amylogenin gene (AMG) indel gender-specific marker was typed in all the samples for quality control monitoring.
PCR reaction setup for hME: For the hME reaction, a total of 25 ng of genomic DNA was Shrimp alkaline phosphatase (SAP) reaction: After PCR, the remaining unincorporated dNTPs were dephosphorylated by adding 2 μl of the SAP cocktail containing 1.53 μl of water, 0.17 μl of hME reaction buffer (Sequenom), and 0.3 μl of SAP (Sequenom). The 384-well plate was then sealed and placed in a thermal cycler under the following conditions: 37°C for 20 min, 85°C for 5 min, and 4°C until hME reaction. hME reaction: After the SAP treatment, a 2 μl cocktail consisting of 1.728 μl water, 0.2 μl hME EXTEND mix containing 10X buffer and appropriate d/ddNTPs (Sequenom), 0.54 μl of 10 μM each extension primer mix and 0.018 μl of 32 U/μl ThermoSequenase (Sequenom) was added.
After the hME cocktail addition, the plate was again sealed and placed in a thermal cycler with the following program: 94°C for 2 min followed by 55 cycles of 94°C for 5 sec, 52°C for 5 sec, and 72°C for 5 sec.
I-PLEX reaction: The extension primers, iPLEX enzyme, iPLEX buffer, and the iPLEX termination mixture of mass-modified dideoxynucleotide triphosphates were added to initiate the iPLEX primer extension reaction. This reaction generates allele-specific primer extension products that are one base longer than the original MassEXTEND primer. The EXTEND mixture (2 μl) was added to the PCR/SAP mixture (7 μl) for a total volume of 9 μl containing 0.222 X iPLEX buffer, 1 X iPLEX termination mix, 0.625 μM to 1.25 μM of each extension primer, and Nanodispensing and mass spectrometry: Following the hME or the I-PLEX extension reactions, the reaction mix was desalted by adding 20 μl of a cationic resin mix (6 mg), SpectroCLEAN (Sequenom). The plate was sealed and placed in a rotating shaker for 10 min for desalting.
Completed genotyping reactions were spotted in nanoliter volumes onto a matrix arrayed silicon chip with 384 elements (Sequenom SpectroCHIP) using the MassARRAY Nanodispenser.
SpectroCHIPS were analyzed using the Bruker Autoflex MALDI-ToF mass spectrometer and the spectra were processed using the SpectroTYPER software (Sequenom).
Data analysis
All data were entered twice and verified. A de-identified data set was created after merging the genetic, phenotypic, and environmental data. SAS® (Cary, NC) was used for the analyses and a P value <0.05 was considered statistically significant. Chi-square analysis and t-tests were used for univariate analyses, and multivariate logistic regression was employed to identify independent risk factors after adjusting for potential confounders. Haplotype analysis was performed using the HAP-Haplotype Resolution version 3.0 24 (http://research.calit2.net/hap/WebServer.htm).
Results
Our LOAD cohort was comprised of 153 cases (mean age 78.2 years) and 302 controls (mean age 87.2 years). Both the case and control groups were selected from PMRP and were carefully phenotyped as detailed previously in materials and methods (baseline characteristics in table 2).
The percent of AD cases that had ever smoked cigarettes was significantly higher than controls (49.3% versus, 38.4%, P <0.03). Highest recorded systolic and diastolic blood pressures and pulse pressures were significantly higher in controls than cases (all P <0.005).
A total of ten SNPs from four genes were tested for associations with LOAD. Genes tested included APOE (rs429358, rs7412), ACE (rs1800764, rs4291, rs464994 [289 bp ALU/-], and rs4343), OLRI (rs3912640, rs2742113, rs1050283), and CYP46 (rs754203). All SNPs tested were within Hardy-Weinberg equilibrium (data not shown).
As expected, the APOE4 allele had the strongest association with increased risk to LOAD 
Stratification by APOE4 status
When stratifying by the presence or absence of the APOE4 allele, obesity at age 50 was found to be positively associated with LOAD only in subjects who carry one or two APOE4 alleles (P = 0.13, 
Discussion
As with other complex diseases, LOAD is not only a genetic disease, but also involves environmental components. In this study a number of genetic and environmental factors were examined to determine their relative contribution to LOAD in our PMRP cohort and to obtain pilot data to estimate needed sample size and staffing for a larger more definitive study. Several important strengths of this cohort are; 1) the homogeneity of the sample population (all subjects were European Caucasians from central Wisconsin with greater than 60% reporting their ethnicity to be German, 2) the LOAD diagnosis for patients was made by a single neurologist (SFM) using NINCDS-ADRDA criteria 1 , 3) the controls from among the cohort were carefully selected after performing an MMSE to exclude any controls with possible signs of dementia who were older, and 4) a complete medical record including all laboratory testing that was electronically available for each patient in the cohort. The majority of the subjects receive their health care exclusively at Marshfield Clinic. A limitation of the pilot cardiovascular risk factors data is that only one measure was extracted. It is possible that lipids or other risk factors are associated with AD at different life points or that medications to lower risk of cardiovascular endpoints may impact LOASD risk.
The ACE gene has been a subject of controversy with respect to its association with AD. Our data confirm that the ACE gene is associated with increased risk to LOAD consistent with the three SNP haplotype TAA reported by Kehoe et al, 6 not including the ALU I/D polymorphism.
More interestingly, the association of the ACE SNPs with LOAD varied by APOE4 allele status.
These pilot data provide preliminary evidence that the ACE gene is an independent risk factor to AD and that gene/gene interaction is potentially occurring. More recently Meng et al 25 reported a very strong association between the ACE gene and LOAD in an Israeli-Arab community where APOE4 is in very low prevalence in both non-demented (2.4%) and demented subjects(3.6%). It is therefore likely that in the absence of APOE4, the ACE gene is a strong risk factor for LOAD.
These data further support our finding that the ACE gene is an independent risk factor to AD.
Recent cross sectional meta-analysis using thousands of samples established that the ACE I/D is associated with LOAD without stratification by APOE4. 7 We also observed an association between the ORL1 and LOAD which varied by APOE4. Again, this finding indicates that ORL1 is an independent risk factor to LOAD and supports the initial finding by Luedecking-Zimmer et al. 8 Interestingly, Bertram et al 26 showed a similar trend, with the APOE4 negative group exhibiting a much smaller P-value than other groups (with one or two copies of APOE4). However, since their study only achieved a trend toward significance for association of ORL1 with LOAD in the APOE4 negative group (P = 0.074), this finding went unrecognized.
Preliminary evidence indicated that the CYP46 intron 2 (rs754203) gene polymorphism is associated with increased brain Abeta load and higher risk of AD. 9, [27] [28] [29] In our cohort, we found that a potential association between CYP46 (rs754203) and LOAD varies by APOE4 allele status. Recently a number of other studies in different populations excluded the association of CYP46 (rs754203) with LOAD. [30] [31] [32] [33] [34] [35] It remains possible that such an association exists, and that CYP46 acts synergistically with APOE4 to increase the risk to LOAD as postulated by some investigators. 9, 28 However, a much larger sample size would be needed to confirm such an interaction.
We analyzed several environmental and personal risk factors before and after stratification by APOE4 allele. After adjustment for the age difference between the cases and controls in multivariate models, blood pressure differences persisted between cases and controls. Smoking showed a positive association with LOAD in subjects without an APOE4 allele. Our findings pertaining to smoking are in line with previous findings, 17, 36 where the incidence of AD was shown to be more than double for smokers compared to non-smokers. Differences in the positive association of smoking and LOAD to studies showing a protective effect of smoking could be due to the stratification of results by APOE 4 observed in the current study.
We found obesity at the age of 50 to be associated with LOAD in subjects who carry an APOE4 allele. A review of the association between dementia and body mass index (BMI) concluded that there is sufficient evidence to support an independent relationship of increased BMI as a risk factor for dementia. 37 Further research to determine if smoking cessation or weight loss results in a decreased risk of LOAD would strengthen these findings. Identification of genetic risk factors has the potential to lead to both preventative and symptomatic treatment approaches targeting specific biochemical mechanisms supporting pathogenic developments. Currently, the mechanism in which APOE, ACE, and ORL1 lead to increased risk for LOAD is unknown, but their definition may lead to development of pertinent models in which the mechanisms for increased risk may be explored. Understanding of mechanisms will lead to therapies targeted at the specific loci in the cascade of pathogenic events leading to LOAD.
In summary, the results from our pilot study suggest that both the ACE and OLR1genes are risk factors for development of LOAD independent of the APOE4 risk allele, and that gene/gene and gene/environment interactions exist with APOE4 allele status that need to be accounted for in study design and analysis in future studies of LOAD. The data from this pilot study can be used to estimate sample size and staffing requirements for larger, more definitive studies. Disclosure Statement: None reported. 
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Amplicon length includes the added 10 mers tail. The small letters in the extension primer for the ACE indel were added to improve mass discrimination in the multiplex reaction. SNP, single nucleotide polymorphism. 
